GSB Wealth Management LLC Sells 8,613 Shares of Pfizer Inc. (NYSE:PFE)

GSB Wealth Management LLC lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,780 shares of the biopharmaceutical company’s stock after selling 8,613 shares during the period. GSB Wealth Management LLC’s holdings in Pfizer were worth $1,312,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. bought a new stake in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC raised its stake in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in shares of Pfizer during the 4th quarter worth approximately $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.6%

PFE stock opened at $24.00 on Wednesday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The stock has a market capitalization of $136.47 billion, a price-to-earnings ratio of 17.39, a PEG ratio of 0.89 and a beta of 0.57. The business’s fifty day moving average price is $23.14 and its two-hundred day moving average price is $24.93. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The company’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.82 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.17%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer’s payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald initiated coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target for the company. Finally, Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.